UBS reiterates Thermo Fisher Scientific stock rating on solid quarter
UBS reiterated a Buy rating and $800 price target for Thermo Fisher Scientific (TMO) after its Q3 results beat expectations. Revenue grew 6% organically, and EPS was $6.68. UBS expects 2026 to outperform 2025, with strong momentum beyond. Despite positive results, the stock declined in premarket trading.
How this was made
The 30-second read
Why it matters
The earnings beat and raised outlook justify UBS's $800 target, potentially driving the stock higher.
Market read
First‑report earnings beat for a large‑cap biotech supplier; likely to influence short‑term price action.
What to watch
Higher pricing pressure from AI‑driven competition could temper long‑term upside.
Background
Thermo Fisher reported Q3 2026 results with 6% organic growth, $12.14 bn revenue and $6.68 EPS, beating estimates.
Ticker impact
UBS reiterated a Buy rating and $800 price target after Thermo Fisher's Q3 earnings beat and raised outlook.
likely upward pressure as investors price in the buy rating and higher target.
Earnings beat, revenue above expectations, and a higher full‑year outlook are fresh, material data for a large‑cap.
Market effects
Positive earnings may lift the life‑sciences equipment sector.
U.S. biotech and industrials could see modest gains.
Limited to investors tracking large‑cap earnings.
Counterpoint
The stock fell in pre‑market despite the beat, suggesting short‑term profit‑taking risk.
Key entities
- companyThermo Fisher Scientific
Life‑sciences equipment and services provider (ticker TMO).
- analystUBS
Investment bank that reiterated a Buy rating and set a $800 price target.
